Study identification

PURI

https://redirect.ema.europa.eu/resource/50801

EU PAS number

EUPAS50800

Study ID

50801

Official title and acronym

DARWIN EU® Prevalence of rare blood cancers in Europe

DARWIN EU® study

Yes

Study countries

Belgium
Germany
Netherlands
Spain
United Kingdom

Study description

In this study the prevalence of rare blood cancers (follicular lymphoma, diffuse large B-Cell lymphoma, multiple myeloma, chronic lymphocytic leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia) will be assessed.

Study status

Finalised
Research institution and networks

Institutions

IQVIA
United Kingdom
First published:
22/04/2024
Institution
Non-Pharmaceutical companyENCePP partner
University of Oxford

Networks

Contact details

Edward Burn

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Data collection

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
EMA
Study protocol
Initial protocol

D2.2.3_DARWIN_EU_Study Protocol C1-001_v2.0_EU_PAS

English (1.04 MB - PDF)View document
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable